Surgical Therapies for Hepatic Colorectal Metastasis

Reference work entry


The liver is the most frequent site of metastases in patients with primary colorectal cancer. Surgical resection for isolated liver disease has become progressively safer, more effective, and potentially curative. Better outcomes have prompted expansion of indications for surgery to include patients in their 70s and 80s, with multi-lobar disease, and with a small future liver remnant that are hypertrophied with portal vein embolization techniques. The clinical risk score takes into account five elements that can better predict and facilitate selection of patients who may benefit the most from surgical resection.

Simultaneous colon and liver resection in synchronous metastases has been demonstrated to be safe and the approach of choice in many high-volume centers. Ablative techniques are also being utilized with good results in patients with smaller tumors and prohibitive operative risk factors or with bilobar disease not amenable to resection. These local therapies are deemed to have better outcomes than chemotherapy alone. However, chemotherapy remains the standard adjuvant therapy in patients with resected stage IV disease. Chemotherapy is also currently being used to downstage patients who initially present with unresectable disease. However, the entity of chemotherapy-associated steatohepatitis (CASH) has been increasingly recognized and therefore preoperative chemotherapy for resectable stage IV disease has not been definitively established as the optimal approach. After resection of liver metastases, the primary sites of recurrence are the liver and lung. The best approach to optimize survival is therefore multimodal with a combination of surgery or ablative techniques for focal disease and systemic adjuvant therapy thereafter.


Liver Metastasis Liver Resection Preoperative Chemotherapy Tumor Ablation Colorectal Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Steele GJ, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspectives. Ann Surg. 1989;210(2):127–38.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991;110:13–29.PubMedGoogle Scholar
  3. 3.
    Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254–62.CrossRefPubMedGoogle Scholar
  4. 4.
    House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hagerstrand I, Ranstam J, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg. 1987;11:541–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Bozzetti F, Bignami P, Morabito A, Doci R, Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Ann Surg. 1987;205:264–70.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery. 1998;124(1):57–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Saltz LB, Clarke S, az-Rubio E, Scheithauer W, Figer A, Wong R. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438–47.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol. 2001;8(4):347–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(10 Suppl):S22–31.PubMedGoogle Scholar
  16. 16.
    Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231(4):487–99.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathological risk factors. Surgery. 1994;116:703–11.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100:278–84.PubMedGoogle Scholar
  21. 21.
    Fortner JG, Fong Y. Twenty-five year follow-up for liver resection: the personal series of Dr. Joseph G. Fortner. Ann Surg. 2009;250:908–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Fong Y, Gonen M, Rubin D, Radzyner D, Brennan MF. Long-term survival is superior after resection for cancer in high volume centers. Ann Surg. 2005;242(4):540–7.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective in the elderly. Ann Surg. 1995;222(4):426–37.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000;7(9):643–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Surg Clin North Am. 1989;69:339–59.CrossRefPubMedGoogle Scholar
  26. 26.
    Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer. 1993;71(S12):4252–66.CrossRefPubMedGoogle Scholar
  27. 27.
    Rosen CB, Nagorney DM, Taswell HF, Helgeson SL, Ilstrup DM, Van Heerden JA, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg. 1992;216:492–505.CrossRefGoogle Scholar
  28. 28.
    Stephenson KR, Steinberg SM, Hughes KS, Vetto JT, Sugarbaker PH, Chang AE. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg. 1988;208:679–87.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26(11):1348–53.CrossRefPubMedGoogle Scholar
  30. 30.
    Arru M, Aldrighetti L, Castoldi R, Di PS, Orsenigo E, Stella M, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg. 2008;32(1):93–103.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen YY, Perera DS, Yan TD, Schmidt LM, Morris DL. Applying Fong’s CRS score in patients with colorectal liver metastases treated by cryotherapy. Asian J Surg. 2006;29:238–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Schussler-Fiorenza CM, Mahvi DM, Niederhuber J, Rikkers LF, Weber SM. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg. 2004;8(2):150–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Jarnagin WR, Conlon K, Bodniewicz J, Dougherty E, DeMatteo RP, Blumgart LH, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer. 2001;91(6):1121–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231(5):743–51.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo R, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. 2003;197(2):233–41.CrossRefPubMedGoogle Scholar
  36. 36.
    Reddy S, Zorzi D, Lum YW, Barbas A, Pawlik T, Ribero D, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16(7):1809–19.CrossRefPubMedGoogle Scholar
  37. 37.
    Martin RC, Augenstein V, Reuter NP, Scoggins CR, McMasters KM. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg. 2009;208(5):842–50.CrossRefPubMedGoogle Scholar
  38. 38.
    Mala T. Cryoablation of liver tumours – a review of mechanisms, techniques and clinical outcome. Minim Invasive Ther Allied Technol. 2006;15(1):9–17.CrossRefPubMedGoogle Scholar
  39. 39.
    Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol. 2004;5(9):550–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2009;17(1):171–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd III GD, Dorfman GS, et al. American society of clinical oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2009;28(3):493–508.CrossRefPubMedGoogle Scholar
  42. 42.
    Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–51.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–8.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15(10):2757–64.CrossRefPubMedGoogle Scholar
  45. 45.
    Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol. 2003;10(4):338–47.CrossRefPubMedGoogle Scholar
  46. 46.
    Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246(4):559–65.CrossRefPubMedGoogle Scholar
  47. 47.
    Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 2008;12(11):1967–72.CrossRefPubMedGoogle Scholar
  48. 48.
    Maeda T, Hasebe Y, Hanawa S, Watanabe M, Nakazaki H, Kuramoto S, et al. Trial of percutaneous hepatic cryotherapy: preliminary report. Nippon Geka Gakkai Zasshi – J Jpn Surg Soc. 1992;93:666.Google Scholar
  49. 49.
    Hohenberger P, Schlag P, Schwarz V, Herfarth C. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. J Surg Oncol. 1990;44:245–51.CrossRefPubMedGoogle Scholar
  50. 50.
    Nordlinger B, Parc R, Delva E, Quilichini M, Hannoun L, Huguet C. Hepatic resection for colorectal liver metastases. Ann Surg. 1987;205:256–63.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Butler J, Attiyeh FF, Daly JM. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet. 1986;162:109–13.PubMedGoogle Scholar
  52. 52.
    Griffith KD, Sugarbaker PH, Chang AE. Repeat hepatic resections for colorectal metastases. Br J Surg. 1990;77:230–3.CrossRefGoogle Scholar
  53. 53.
    Fortner JG. Recurrence of colorectal cancer after hepatic resection. Am J Surg. 1988;155:378–82.CrossRefPubMedGoogle Scholar
  54. 54.
    Lange JF, Leese T, Castaing D, Bismuth H. Repeat hepatectomy for recurrent malignant tumors of the liver. Surg Gynecol Obstet. 1989;169:119–26.PubMedGoogle Scholar
  55. 55.
    Pastana C, Reitmeier RJ, Moertel CG, et al. The natural history of carcinoma of the colon and rectum. Am J Surg. 1964;108:826–9.CrossRefGoogle Scholar
  56. 56.
    Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancers. Arch Surg. 1976;111:330–4.CrossRefGoogle Scholar
  57. 57.
    Scheele J, Strangl R, Altendor-Hofman A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on natural history. Br J Surg. 1990;77:1241–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Rivoire M, De CF, Meeus P, Negrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002;95(11):2283–92.CrossRefPubMedGoogle Scholar
  59. 59.
    Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003;10(9):1059–69.CrossRefPubMedGoogle Scholar
  60. 60.
    Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24(31):4976–82.CrossRefPubMedGoogle Scholar
  62. 62.
    Park R, Gonen M, Kemeny N, Jarnagin W, D’Angelica M, DeMatteo R, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204:753–61.CrossRefGoogle Scholar
  63. 63.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Kemeny MM, Adak S, Lipsitz S, MacDonald J, Benson AB. Results of the intergroup [Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal metastases. Proc Am Soc Clin Oncol. 1999;18:264a. Abstract.Google Scholar
  65. 65.
    Bozzetti F, Bignami P, Montalto F, Doci R, Gennari L. Repeated hepatic resection for recurrent metastases from colorectal cancer. Br J Surg. 1992;79(2):146–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224(4):509–20.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery. 2002;131(4):433–42.CrossRefPubMedGoogle Scholar
  69. 69.
    Kemeny NE, Huitzil Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Tabernero J, Van CE, az-Rubio E, Cervantes A, Humblet Y, Andre T, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25(33):5225–32.CrossRefPubMedGoogle Scholar
  72. 72.
    Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg. 2006;243(1):8–9.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg. 2009;16(2):137–44CrossRefPubMedGoogle Scholar
  74. 74.
    Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97(8):1035–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of SurgeryRobert Wood Johnson and the Cancer Institute of New JerseyNew BrunswickUSA
  2. 2.Department of Surgery and RadiologyMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations